New drug cocktail aims to beat Hard-to-Treat leukemia
NCT ID NCT04231851
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two drugs—CPX-351 (a chemotherapy) and glasdegib (a targeted pill)—in 30 people with acute myeloid leukemia (AML) that is either linked to a prior blood disorder or caused by previous cancer treatment. The main goal is to see how many patients are alive and cancer-free after 6 months. The study is active but no longer recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPX-351 (a chemotherapy drug combo) and glasdegib (a targeted therapy pill)
What this could lead to
If successful, this combination could offer a new treatment option for people with certain types of AML that are harder to treat.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drugs can cause serious side effects, and it's not yet known if the combination works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States